Allometric scaling of preclinical pharmacokinetic and toxicokinetic parameters to predict clinical pharmacokinetics of BXQ-350 saposin C protein-phosphatidylserine nanovesicles.

Charles A Cruze,Olivier Rixe,John C. Morris,Vinay K. Puduvalli,John L. Villano,Trisha M. Wise-Draper,Angela N. Johnson,Robert Wesolowski,Gary A. Thompson

Allometric scaling of preclinical pharmacokinetic and toxicokinetic parameters to predict clinical pharmacokinetics of BXQ-350 saposin C protein-phosphatidylserine nanovesicles.

2018

Charles A Cruze
Olivier Rixe
John C. Morris
Vinay K. Puduvalli
John L. Villano
Trisha M. Wise-Draper
Angela N. Johnson
Robert Wesolowski
Gary A. Thompson

e14537Background: Interspecies allometric scaling is used to extrapolate pharmacokinetics (PK) from preclinical data to human PK and dosing. Efficacy of BXQ-350, a novel Saposin C phosphatidylserin...

Keywords:

Toxicokinetics
Dosing
Pathology
Phosphatidylserine
Medicine
Pharmacology
Pharmacokinetics
c protein
preclinical data

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations